News Incyte gobbles up Star's Vega haematology unit in $2bn deal Incyte has agreed to buy Star Therapeutics' Vega subsidiary for $1.25bn upfront, adding a late-stage drug candidate for bleeding disorder VWD.
News Crystalys emerges with $205m, and other biofinancings Recent biotech financings include big rounds for Crystalys and Star Therapeutics, with Sparrow, Avenzo, and Aerska also raising new funds.
News Apollo, Nimbus lead bumper week for biotech financings This week saw a series of big-ticket funding rounds for biotech companies, with Apollo Therapeutics and Nimbus Therapeutics both pulling in upwards of $200 million, in a p
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.